U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H26N2O5S
Molecular Weight 394.485
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RBX-9001

SMILES

CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC=C(O)C(=C2)S(N)(=O)=O

InChI

InChIKey=UIDNSBDGPKUJHU-CQSZACIVSA-N
InChI=1S/C19H26N2O5S/c1-3-25-17-6-4-5-7-18(17)26-11-10-21-14(2)12-15-8-9-16(22)19(13-15)27(20,23)24/h4-9,13-14,21-22H,3,10-12H2,1-2H3,(H2,20,23,24)/t14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H26N2O5S
Molecular Weight 394.485
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:35:48 GMT 2023
Edited
by admin
on Sat Dec 16 11:35:48 GMT 2023
Record UNII
L3ZWN2HON0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RBX-9001
Common Name English
RBX9001
Code English
RANBAXY-9001
Code English
5-((2R)-2-(2-(2-ETHOXYPHENOXY)ETHYLAMINO)PROPYL)-2-HYDROXY-BENZENESULFONAMIDE
Systematic Name English
BENZENESULFONAMIDE, 5-((2R)-2-((2-(2-ETHOXYPHENOXY)ETHYL)AMINO)PROPYL)-2-HYDROXY-
Systematic Name English
Code System Code Type Description
CAS
176223-33-9
Created by admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
PRIMARY
FDA UNII
L3ZWN2HON0
Created by admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
PRIMARY
PUBCHEM
9800777
Created by admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
PLASMA
PARENT -> METABOLITE
URINE
Related Record Type Details
ACTIVE MOIETY
RBx9001; Indication: Urology; Development Stage: Pre-clinical stage
ACTIVE MOIETY
Originator: Ranbaxy Laboratories; Mechanism of Action: Undefined mechanism; Highest Development Phase: Discontinued for Benign prostatic hyperplasia; Most Recent Events: 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company, 02 May 2004 Phase-I clinical trials in Benign prostatic hyperplasia in India (unspecified route), 02 May 2004 Ranbaxy has received approval from the Drugs Controller General of India to begin phase I trials with RBx 9001